Delving into the Latest Updates on Menarini Von Heyden GmbH with Synapse

作者: Oppelt, Melanie ; Beyreuther, Elke ; Schürer, Michael ; Laschinsky, Lydia ; Leßmann, Elisabeth ; Karsch, Leonhard ; Richter, Christian ; Pawelke, Jörg

Regarding the long-term goal to develop and establish laser-based particle accelerators for a future radiotherapeutic treatment of cancer, the radiobiological consequences of the characteristic short intense particle pulses with ultra-high peak dose rate, but low repetition rate of laser-driven beams have to be investigated. This work presents in vitro experiments performed at the radiation source ELBE (Electron Linac for beams with high Brilliance and low Emittance). This accelerator delivered 20-MeV electron pulses with ultra-high pulse dose rate of 10(10) Gy/min either at the low pulse frequency analogue to previous cell experiments with laser-driven electrons or at high frequency for minimizing the prolonged dose delivery and to perform comparison irradiation with a quasi-continuous electron beam analogue to a clinically used linear accelerator. The influence of the different electron beam pulse structures on the radiobiological response of the normal tissue cell line 184A1 and two primary fibroblasts was investigated regarding clonogenic survival and the number of DNA double-strand breaks that remain 24 h after irradiation. Thereby, no considerable differences in radiation response were revealed both for biological endpoints and for all probed cell cultures. These results provide evidence that the radiobiological effectiveness of the pulsed electron beams is not affected by the ultra-high pulse dose rates alone.

100 项与 Menarini Von Heyden GmbH 相关的药物交易

登录后查看更多信息

100 项与 Menarini Von Heyden GmbH 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

2

临床1期

临床2期

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Brain cancer vaccine(University of Pittsburgh Medical Center)	胶质母细胞瘤更多	临床2期
MEN-1611 ( PI3K family )	结直肠癌更多	临床2期
Tagraxofusp-ERZS ( CD123 )	原发性骨髓纤维化更多	临床2期
Dapolsertib ( FLT3 x PIM )	急性髓性白血病更多	临床2期
Felezonexor ( XPO1 )	实体瘤更多	临床1期